THC Stock Analysis — Tenet Healthcare
Sector: Healthcare
AI Verdict
THC is cheap for the growth you're getting, but the moat relies on regulatory stability and local dominance — if either cracks, the low multiple could get even lower.
Competitive Moat
Tenet Healthcare operates a network of hospitals and ambulatory surgery centers, benefiting from local scale and insurance contracting leverage in key regional markets. Its moat comes from high barriers to entry in hospital operations and established payer relationships, which make it difficult for new competitors to replicate its footprint.
Summary
THC stands out for trading at just 11x next year's earnings while still posting nearly double-digit EPS growth forecasts.
Where It Stands
With a forward P/E of 11.0x versus the healthcare sector median of 22x and analyst consensus for 9.4% EPS growth, THC is priced at a steep discount to peers.
Key Metrics
- Trailing P/E: 12.0x
- Forward P/E: 11.0x
- PEG Ratio: 1.28
- Earnings Growth: +0.1%
- Revenue Growth: +0.1%
- 52-Week High: $247.21
- 52-Week Low: $146.60
Analyst Consensus
23 Buy · 4 Hold · 0 Sell (27 analysts)
Bull Case
The 9.4% forward EPS growth at an 11.0x forward P/E means you're getting growth at a price usually reserved for no-growth healthcare names.
Bear Case
If the market re-rates THC to a lower multiple or growth stalls, even a drop to a 9x P/E would cut the stock's value by 18%.
Catalyst to Watch
Watch for regulatory changes or reimbursement rate updates, as these could directly affect both margins and the defensibility of Tenet's regional scale.